Baltimore, MD - August 17, 2009 - Profectus BioSciences, Inc. (Profectus), a clinical stage biopharmaceutical company focused on the development of novel vaccine candidates for serious infections, announced today that the company will present preclinical data at the ImVacs Immunotherapeutics & Vaccine Summit. The conference is taking place from August 17-19, 2009 in Providence, RI. For more information about the conference, please visit http://www.healthtech.com/imt/overview.aspx.
Oral Presentation
: Who: Michael A. Egan, Ph.D., Director of Immunology of Profectus BioSciences
Title:"Progress Towards the Development of an Effective pDNA Prime, Live Vector Boost Vaccination Strategy for the Treatment and Prevention of Infectious Diseases and Cancer"
Track: Novel Vaccines: Adjuvants & Delivery Systems
When: Wednesday, August 19, 2009 at 4:30 p.m.
Where: Renaissance Providence Hotel, Providence, RI
Michael A. Egan, Ph.D., Director of Immunology of Profectus BioSciences, commented, "Profectus' proprietary vaccine candidates have demonstrated encouraging results in preclinical models for HCV and HIV, and have shown dramatic increases in the magnitude and duration of immunologic response with our pDNA or rVSV platforms, used alone or sequentially as a prime-boost. The Company has made significant progress in advancing our vaccine programs in Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV), and we are excited to have the opportunity to present our research findings at the Immunotherapeutics & Vaccine Summit."
About Profectus BioSciences, Inc.
Profectus BioSciences is an innovative research and development vaccine company devoted to advancing the treatment and prevention of chronic infectious diseases. The Profectus proprietary vaccine design approach combines its pDNA and rVSV platforms via a unique prime/boost strategy to advance vaccine research. Profectus' broad development pipeline will address human immunodeficiency virus (HIV), hepatitis C virus (HCV), human papilloma virus (HPV) herpes simplex virus (HSV) and malaria. The Company's first clinical vaccine candidate for HIV is planned for clinical trials in Q4'09/Q1'10 followed by a future therapeutic HCV vaccine.
The Profectus portfolio has received over $100 million in funding from multiple sources, including the National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime-boost vaccines and its anti- inflammatory small molecules for cancer and chronic viral diseases. For more information, please visit: http://www.profectusbiosciences.com.
Oral Presentation
: Who: Michael A. Egan, Ph.D., Director of Immunology of Profectus BioSciences
Title:"Progress Towards the Development of an Effective pDNA Prime, Live Vector Boost Vaccination Strategy for the Treatment and Prevention of Infectious Diseases and Cancer"
Track: Novel Vaccines: Adjuvants & Delivery Systems
When: Wednesday, August 19, 2009 at 4:30 p.m.
Where: Renaissance Providence Hotel, Providence, RI
Michael A. Egan, Ph.D., Director of Immunology of Profectus BioSciences, commented, "Profectus' proprietary vaccine candidates have demonstrated encouraging results in preclinical models for HCV and HIV, and have shown dramatic increases in the magnitude and duration of immunologic response with our pDNA or rVSV platforms, used alone or sequentially as a prime-boost. The Company has made significant progress in advancing our vaccine programs in Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV), and we are excited to have the opportunity to present our research findings at the Immunotherapeutics & Vaccine Summit."
About Profectus BioSciences, Inc.
Profectus BioSciences is an innovative research and development vaccine company devoted to advancing the treatment and prevention of chronic infectious diseases. The Profectus proprietary vaccine design approach combines its pDNA and rVSV platforms via a unique prime/boost strategy to advance vaccine research. Profectus' broad development pipeline will address human immunodeficiency virus (HIV), hepatitis C virus (HCV), human papilloma virus (HPV) herpes simplex virus (HSV) and malaria. The Company's first clinical vaccine candidate for HIV is planned for clinical trials in Q4'09/Q1'10 followed by a future therapeutic HCV vaccine.
The Profectus portfolio has received over $100 million in funding from multiple sources, including the National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime-boost vaccines and its anti- inflammatory small molecules for cancer and chronic viral diseases. For more information, please visit: http://www.profectusbiosciences.com.
